Literature DB >> 8031028

Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro.

T Mazzulli1, S Rusconi, D P Merrill, R T D'Aquila, M Moonis, T C Chou, M S Hirsch.   

Abstract

We compared the in vitro efficacies of two-, three-, and four-drug combinations given continuously or in alternating regimens against a clinical isolate of human immunodeficiency virus type 1. In H9 cells and peripheral blood mononuclear cells, at the drug concentrations used in this study, there was greater suppression of human immunodeficiency virus type 1 infection as the number of drugs in the regimen was increased from one to four simultaneously administered agents. Although alternating drug regimens were effective, they were not better than continuous administration of either single drugs or combinations of agents and were less effective than giving all drugs of an alternating regimen simultaneously.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031028      PMCID: PMC284521          DOI: 10.1128/AAC.38.4.656

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine.

Authors:  M S Smith; E L Brian; J S Pagano
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

3.  Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

Authors:  K L Hartshorn; M W Vogt; T C Chou; R S Blumberg; R Byington; R T Schooley; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  On the determination of availability of ligand binding sites in steady-state systems.

Authors:  T C Chou
Journal:  J Theor Biol       Date:  1977-03-21       Impact factor: 2.691

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Authors:  T J Dueweke; S M Poppe; D L Romero; S M Swaney; A G So; K M Downey; I W Althaus; F Reusser; M Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

Authors:  W Y Gao; T Shirasaka; D G Johns; S Broder; H Mitsuya
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

10.  A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

Authors:  R Yarchoan; J A Lietzau; B Y Nguyen; O W Brawley; J M Pluda; M W Saville; K M Wyvill; S M Steinberg; R Agbaria; H Mitsuya
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

View more
  8 in total

Review 1.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 3.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 4.  Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.

Authors:  D W Notermans; R van Leeuwen; J M Lange
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

5.  Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Christopher Kollmann; Yongbiao Guan; Ting-Chao Chou; Bahige M Baroudy; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.

Authors:  Ajay Singh; Hilliard L Kutscher; Julia C Bulmahn; Supriya D Mahajan; Guang S He; Paras N Prasad
Journal:  Nanomedicine       Date:  2020-02-13       Impact factor: 5.307

7.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.

Authors:  Cécile L Tremblay; Danielle L Poulin; Jennifer L Hicks; Subajini Selliah; Annie Chamberland; Françoise Giguel; Christopher S Kollmann; Ting Chao Chou; Huajin Dong; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.